Medindia
Medindia LOGIN REGISTER
Advertisement

Parkhurst NuVision to Perform Highly Anticipated National Launch of New Permanent Contact Lens for Astigmatism

Friday, September 21, 2018 General News
Advertisement
San Antonio-based vision correction facility will be the first practice in the country to offer the FDA-approved lens to patients in November 2018.
Advertisement

SAN ANTONIO, Sept. 21, 2018 /PRNewswire-PRWeb/ -- Parkhurst NuVision, a San Antonio, Texas-based vision correction facility, has been chosen to perform the highly anticipated national launch of a new permanent contact lens for myopia and astigmatism in one. Dr. Greg Parkhurst will be the first surgeon in the nation to offer the Visian toric ICL to his patients in November 2018. The Visian Toric ICL, a variant of Visian ICL technology created by STAAR Surgical, has been approved by the FDA and allows surgeons to treat astigmatism while simultaneously correcting vision.
Advertisement

"The Visian ICL represents a permanent contact lens that has been available for over a decade. The procedure has helped hundreds of thousands of patients enjoy life free from glasses or contacts. However, it has not been a particularly good option for patients with significant astigmatism…until now," says Greg Parkhurst, MD, a leading San Antonio LASIK specialist and one of the most experienced Visian surgeons in America. "With the FDA-approved Visian Toric ICL, surgeons will now be able to use this excellent procedure to treat moderate and even high astigmatism during the vision correction process."

The Visian technology is similar to LASIK in that it is a long-term vision correction solution. During LASIK, the shape of the eye's surface (cornea) is changed to correct the patient's vision. The Visian is made of a collagen co-polymer, similar to collagen in the rest of the body, so it is biocompatible. The permanent contact lens is placed just beneath the surface of the eye to achieve vision correction.

"The FDA's approval of STAAR Surgical's Visian Toric ICL in the U.S. provides an intuitive treatment option for myopic patients with astigmatism in search of visual freedom," adds STAAR Surgical's President and CEO Caren Mason. "We are thrilled to be offering this lens in the United States, and look forward to officially making the Visian Toric ICL available to U.S. surgeons for their patients."

As a Visian ICL surgery center, Parkhurst NuVision serves patients in San Antonio, Austin, New Braunfels, Eagle Pass, Laredo, Corpus Christi, Uvalde and other Texas communities, as well as patients from across the country and even around the world. Further, STAAR Surgical has added its seal of approval to state Dr. Parkhurst is the most experienced Visian ICL surgeon in the Lone Star State, citing the fact that surgeons have traveled to San Antonio from countries in Europe, Asia and South America to learn Visian ICL treatment methods from Dr. Parkhurst himself.

"For several years now, ICL surgery has been an excellent choice for our San Antonio patients seeking ultra-high-definition vision correction," says Parkhurst NuVision Clinic Director Roberto "Bobby" Saenz, O.D., M.S., F.A.A.O. "We waited until we moved back home to San Antonio, so that Dr. Parkhurst could perform ICL surgery on my wife. She loves it, being able to wake up in the middle of the night to get our 1 year old daughter without having to look for her glasses is awesome."

Dr. Parkhurst's wife has had ICL as well. "With so many people across the country who have been waiting for access to such a life-changing technology, we are excited to share the good news with the many people on our Toric ICL waiting list, and offer them the procedure right here in San Antonio."

Parkhurst NuVision is located at 9725 Datapoint Drive Suite 200 in San Antonio and can be reached by calling (210) 615-9358. For more information visit http://www.ParkhurstNuVision.com.

 

SOURCE Parkhurst NuVision

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close